Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

NCT05564117 · Completed

Last updated 2026-05-28

This study is testing how well semaglutide tablets taken once daily work to reduce body weight in adults who are overweight or have obesity.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 307 people

Who can join Ages 18+ · all sexes

Timeline Started 2022-10 · est. completion 2024-05

Where 23 sites · Canada, Germany, Poland, United States

What this study is testing ClinicalTrials.gov NCT05564117 ↗

Description as written by the study sponsor.

This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screening period, 64 weeks of treatment period and 7 weeks of follow up period.

Treatments tested

Semaglutide Drug

Semaglutide tablets orally once daily for 64 weeks.
Placebo semaglutide Drug

Semaglutide placebo-matching tablets orally once daily for 64 weeks.

Main thing measured	Percentage Change in Body Weight
Sponsor	Novo Nordisk A/S
Conditions studied	Overweight, Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05564117 ↗